Smoking history effect on peripheral lung inflammation and gene transcription in chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 174, Issue 1, 2006, Pages 2-3

  Caramori, Gaetano ^a   Papi, Alberto ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR AP 1;

CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; EDITORIAL; FOLLOW UP; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSCRIPTION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LUNG ALVEOLUS CELL; LUNG FUNCTION; OXIDATIVE STRESS; PATHOGENESIS; PHOSPHORYLATION; PNEUMONIA; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION; SMOKING HABIT;

HUMANS; NF-KAPPA B; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESEARCH DESIGN; SMOKING; TRANSCRIPTION FACTOR AP-1;

EID: 33745451137     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.2604001     Document Type: Editorial

References (16)

1. Szulakowski P, Crowther AJL, Jiménez LA, Donaldson K, Mayer R, Leonard TB, MacNee W, Drost EM. The effect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:41-50.
2. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res 2002;4:149-159.
3. Furberg H, Sullivan PF, Maes H, Prescott CA, Lerman C, Bulik C, Kendler KS. The types of regular cigarette smokers: a latent class analysis. Nicotine Tob Res 2005;7:351-360.
4. Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J, Benowitz N. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann Intern Med 2004;140:426-433.
5. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1304-1309.
6. Varani K, Caramori G, Vincenzi F, Adcock IM, Casolari P, Leung E, MacLennan S, Gessi S, Morello S, Barnes PJ, et al. Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:398-406.
7. Caramori G, Adcock IM, Ito K. Anti-inflammatory inhibitors of IkappaB kinase in asthma and COPD. Curr Opin Investig Drugs 2004;5:1141-1147.
8. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004;200:689-695.
9. Adcock IM. Transcription factors as activators of gene transcription: AP-1 and NF-kappa B. Monaldi Arch Chest Dis 1997;52:178-186.
10. Demoly P, Chanez P, Pujol JL, Gauthier-Rouviere C, Michel FB, Godard P, Bousquet J. Fos immunoreactivity assessment on human normal and pathological bronchial biopsies. Respir Med 1995;89:329-335.
11. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Bethesda, MD: National Heart, Lung, and Blood Institute; 2001. NIH Publication No. 2701:1-100. Available at: http://www.goldcopd.com (accessed March 31, 2006).
12. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004;56:515-548.
13. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709-721.
14. Shapiro SD, Ingenito EP. The pathogenesis of chronic obstructive pulmonary disease: advances in the past 100 years. Am J Respir Cell Mol Biol 2005;32:367-372.
15. Spurzem JR, Rennard SI. Pathogenesis of COPD. Semin Respir Crit Care Med 2005;26:142-153.
16. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946. [Published erratum appears in Eur Respir J 2006;27:242.]